

stroke, ischemic stroke, and damages caused by surgery, and wherein said human is one having such an injury.

*Sub E1*  
*cut*  
*D1*  
4 (Thrice-Amended). A method in accordance with claim 16, wherein said method is for ameliorating the degenerative effects on the central nervous system or the peripheral nervous system of a disease selected from the group consisting of diabetic neuropathy, senile dementia, Alzheimer's disease, Parkinson's Disease, facial nerve (Bell's) palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, non-arteritic optic neuropathy, and vitamin deficiency, and wherein said human is one having such a disease.

5 (Thrice-Amended). A method in accordance with claim 16, wherein said method is for ameliorating the degenerative effects of a disease on the central nervous system or the peripheral nervous system, wherein said disease is other than an autoimmune disease or a neoplasm, and wherein said human is one having such disease. *abasis?*

Rewrite amended claim 16 in twice-amended form as follows:

*D2* *Sub E2*  
16 (Twice-amended). A method of ameliorating the degenerative effects of injury or disease on the central nervous system or peripheral nervous system, by preventing or inhibiting axonal degeneration and/or promoting nerve

regeneration, wherein said injury or disease is other than an autoimmune disease or a neoplasm, comprising administering to a human having such an injury or disease an effective amount for neuroprotection of a composition comprising an agent selected from the group consisting of:

- cnr  
D<sub>2</sub>
- (a) non-recombinant, NS-specific antiseif activated T-cells;
  - (b) a NS-specific antigen or a derivative thereof;
  - (c) a peptide derived from a NS-specific antigen or a derivative thereof;
  - (d) a nucleotide sequence encoding a NS-specific antigen;
  - (e) a nucleotide sequence encoding a peptide derived from a NS-specific antigen; and
  - (f) any combination of (a)-(e).
- Sub E2  
cnr

Delete claim 10 and substitute therefor new claim 20 as follows:

D<sub>3</sub>

20 (New). The method according to claim 17 in which said NS-specific antigen is administered concurrently with administration of the composition comprising an agent of (a), (c), (d) or (e).